share_log

BioNTech | 6-K: Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

BioNTech | 6-K:外國發行人報告
美股SEC公告 ·  04/08 07:17
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息